

testosterone (Testopel)**Medical Benefit Drug Policy****Place of Service**

Office Administration

Outpatient Facility Administration

Drug Details**USP Category:** HORMONAL AGENTS, STIMULANT/REPLACEMENT/MODIFYING (SEX HORMONES/MODIFIERS)**Mechanism of Action:** Testosterone replacement**HCPCS:**

J1073:Testosterone pellet, implant, 75 mg

How Supplied:

Testosterone pellets each containing 75mg testosterone. One pellet per vial in boxes of 10 and 100

Condition(s) listed in policy *(see coverage criteria for details)*

- Testosterone Replacement

Any condition not listed in this policy requires a review to confirm it is medically necessary. For conditions that have not been approved for intended use by the Food and Drug Administration (i.e., off-label use), the criteria outlined in the California Code of Regulations (CCR), Title 22, Section 51303 and 51313 must be met.

Special Instructions and Pertinent Information

Provider must submit documentation (such as office chart notes, lab results or other clinical information) to ensure the member has met all medical necessity requirements.

The member's specific benefit may impact drug coverage. Other utilization management processes, and/or legal restrictions may take precedence over the application of this clinical criteria.

Coverage Criteria**The following condition(s) require Prior Authorization/Preservice.****Testosterone Replacement****Meets medical necessity if all the following are met:**

1. Being used for male hypogonadism or testosterone replacement therapy for transgender patient
2. Inadequate response or intolerance to a generic long-acting testosterone injection (e.g. IM testosterone cypionate, IM testosterone enanthate)
3. Inadequate response or intolerance to a topical testosterone (e.g. testosterone 1% gel)

Covered Doses:

1200 mg given by SC implantation every 3 to 6 months

Coverage Period:

Yearly, based on continued response to therapy

ICD-10:

E29.1, F64.0, F64.1, F64.8, F64.9

References

1. AHFS. Available by subscription at <http://www.lexi.com>
2. Coleman E, Radix AE, Bouman WP, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022 Sep 6;23(Suppl 1): S1-S259.
3. DrugDex. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
4. Mulhall JP, Trost LW, Brannigan RE et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol 2018; 200: 423.
5. Shalender Bhasin, Juan P Brito, Glenn R Cunningham et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 103, Issue 5, May 2018, 1715-1744.
6. Testopel (testosterone) [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc; July 2025.

Review History

Date of Last Annual Review: 3Q2025

Changes from previous policy version:

- HCPCS: Added J1073, effective 1/1/2026.

*Blue Shield of California Medication Policy to Determine Medical Necessity
Reviewed by P&T Committee*